Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121170 | 0.95 | TSHR (0.44) | ESR1ALDH1A1TSHRNPSR1MEN1 | |
| SCHEMBL5124266 | 0.86 | BCDIN3D (0.42) | ESR1ALDH1A1TSHRNPSR1MEN1 | |
| SCHEMBL5117638 | 0.86 | ALDH1A1 (0.47) | CHRM4ALDH1A1TSHRNPSR1MEN1 | |
| SCHEMBL5128242 | 0.86 | ALDH1A1 (0.42) | CHRM4ESR1ALDH1A1TSHRNPSR1 | |
| SCHEMBL5122240 | 0.85 | ESR1 (0.48) | ESR1PDE10A | |
| SCHEMBL5128127 | 0.85 | NOS2 (0.49) | CHRM4ESR1ALDH1A1TSHRNPSR1 | |
| SCHEMBL5120030 | 0.84 | CHRM4 (0.42) | CHRM4ALDH1A1TSHRNPSR1MEN1 | |
| SCHEMBL5118869 | 0.84 | CHRM4 (0.43) | CHRM4ALDH1A1TSHRNPSR1MEN1 | |
| SCHEMBL5782312 | 0.82 | HTT (0.45) | CHRM4ALDH1A1TSHRNPSR1MEN1 | |
| SCHEMBL5122264 | 0.82 | ESR1 (0.48) | CHRM4ESR1ALDH1A1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | CHRM4 4573/4885ESR1 2256/4885ALDH1A1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.